SciSparc Ltd (SPRC) News

Form 425 - Prospectuses and communications, business combinations

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax’s Direct Import Agreement with Major Chinese Vehicle Manufacturer

To date, SciSparc has advanced $4.25 million to Automax under the Bridge Loan agreement and amendments thereto...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

Pioneering Therapeutic Approach Aims to Enhance Safety and Efficacy in Mental Health and Addiction Treatments...

Form EFFECT - Notice of Effectiveness

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination

TEL AVIV, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc...

Form F-1 - Registration statement for certain foreign private issuers

SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million

SciSparc would be entitled to receive consideration valued at $3 million in Polyrizon securities, as well as...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome

SciSparc to conduct the trial at the Yale Child Study Center at the Yale School of Medicine in the USA...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board

Professor Peled is the Director of the Oncology Department at the Shaare Zedek Medical Center, Jerusalem...